Enanta Pharmaceuticals to Unveil Preclinical Data for KIT Inhibitor EDP-978 at AAAAI 2026
Event summary
- Enanta Pharmaceuticals will present preclinical data for EDP-978, its KIT inhibitor for Type 2 immune diseases, at the 2026 AAAAI Annual Meeting on February 27.
- Two poster presentations will detail the compound's potency, selectivity, and pharmacokinetic profile.
- EDP-978 is part of Enanta's immunology pipeline targeting key drivers of the Type 2 immune response.
- Enanta's royalties from HCV products developed with AbbVie fund ongoing operations.
The big picture
Enanta Pharmaceuticals is leveraging its chemistry-driven approach to develop small molecule drugs for viral infections and immunological diseases. The presentation of preclinical data for EDP-978 at the AAAAI 2026 meeting highlights the company's focus on targeting key drivers of the Type 2 immune response. With a robust pipeline and ongoing funding from HCV product royalties, Enanta aims to establish itself as a leader in the discovery and development of innovative treatments for inflammatory diseases.
What we're watching
- Clinical Translation
- How the preclinical data for EDP-978 will translate into clinical efficacy and safety in human trials.
- Competitive Positioning
- Whether Enanta can differentiate EDP-978 in the crowded space of Type 2 immune disease treatments.
- Pipeline Progression
- The pace at which Enanta advances EDP-978 through development stages and potential regulatory milestones.
Related topics